


MFG Global Plus (USD)

Portfolio Manager	Strategy Inception Date	Total Strategy Assets	Total Global Assets ¹
Hamish Douglass	1 July 2013	USD \$6,609.3 million	USD \$41,159.2 million


Objective	Approach
Capital preservation in adverse markets	High conviction (20-40 securities), high quality focus
Pre-fee return of 10%p.a. through the economic cycle	Dual-sleeve portfolio construction with dynamic allocation to cash (max 20%) Combined Risk Ratio cap of 0.8^

Strategy Fundamentals ²	Strategy	Index
Number of Holdings	23	1,640
Return on Equity	27	17
P/E Ratio (1 year forward)	19.6	15.6
Interest Cover	14	11
Debt/Equity Ratio	44	49
Active Share	87	n/a
Weighted Average Market Cap (USD million)	280,361	n/a

Top 10 Holdings ²	Sector ²	%
Alphabet Inc	Internet & eCommerce	6.8
Facebook Inc-A	Internet & eCommerce	6.2
Apple Inc	Information Technology	5.8
Visa Inc	Payments	5.5
Starbucks Corp	Consumer Defensive	5.3
Lowe's Co Inc	Consumer Discretionary	4.9
Kraft Heinz Co	Consumer Defensive	4.4
HCA Healthcare Inc	Health Care	4.3
Microsoft Corp	Information Technology	4.0
MasterCard Inc	Payments	4.0
TOTAL:		51.2



Capital Preservation Measures ⁴	3 Years	5 Years	Since Inception
Adverse Markets			
No of observations	8	14	14
Outperformance consistency	88%	93%	93%
Average return – Strategy	-2.4%	-1.4%	-1.4%
Average return – Benchmark	-3.5%	-3.4%	-3.4%
Down Market Capture	0.7	0.4	0.4
Drawdown			
Maximum Drawdown - Strategy	-6.2%	-7.3%	-7.3%
Maximum Drawdown - Index	-8.8%	-12.0%	-12.0%



Cumulative Performance ³	3 Months (%)	1 Year (%)	3 Years (% p.a.)	5 Years (% p.a.)	Since Inception (% p.a.)
Composite (Gross)	7.3	17.5	14.8	11.7	12.0
Composite (Net)	7.1	16.5	13.9	10.9	11.1
MSCI World NTR Index	5.0	11.2	13.5	9.3	10.5
Excess (Gross)	2.3	6.3	1.3	2.4	1.5
MSCI World Qual. Mix NTR	5.7	11.6	13.5	10.1	10.9
MSCI Min. Vol. NTR	6.0	10.3	12.1	10.2	10.4

Annual Performance ³	CYTD (%)	2017	2016	2015	2014	2013*
Composite (Gross)	10.4	25.6	4.3	3.9	6.6	13.4
Composite (Net)	9.8	24.6	3.4	3.0	5.8	12.9
MSCI World NTR Index	5.4	22.4	7.5	-0.9	4.9	16.8
Excess (Gross)	5.0	3.2	-3.2	4.8	1.7	-3.4
MSCI World Qual. Mix NTR	5.5	21.5	7.9	1.6	7.3	14.3
MSCI Min. Vol. NTR	5.7	17.3	7.5	5.2	11.4	7.9

Supplementary Statistical Measures ⁵	3 Years	5 Years	Since Inception
Beta	0.9	0.9	0.9
Tracking Error (% p.a.)	4.2%	4.0%	4.1%
Standard Deviation – Strategy	8.7%	9.3%	9.3%
Information Ratio	0.3	0.6	0.4

1 Comprised of all Global Strategies.

2 The data is based on a representative portfolio for the strategy. The representative portfolio changed in July 2017 due to the closure of the former representative portfolio. Sectors are internally defined. Geographical exposure is calculated on a look through basis based on underlying revenue exposure of individual companies held within the portfolio. The Index is the MSCI World NTR Index. Refer to the Important Notice below for further information.

3 Returns are for the Global Plus Composite and denoted in USD. Performance would vary if returns were denominated in a currency other than USD. Refer to the GIPS Disclosure section below for further information. Composite (Net) returns are net of fees charged to clients and have been reduced by the amount of the highest fee charged to any client employing that strategy during the period under consideration. Actual fees may vary depending on, among other things, the applicable fee schedule and portfolio size. Fees are available upon request.

4 Risk measures are calculated before fees and in USD. An adverse market is defined as a negative quarter, rolled monthly, for the MSCI World Net TR USD Index, whilst drawdown measures are measured monthly.

5 Supplementary Statistical Measures Beta, Tracking Error and Information Ratio are calculated in USD using the MSCI World NTR Index.

^ Combined risk ratio is a measure of relative beta and relative drawdown to MSCI World NTR USD Index. Please contact MFGAM should you wish for further details on the calculation.

* Returns are only for part year.

IMPORTANT NOTICE

This material is being furnished to you to provide summary information regarding Magellan Asset Management Limited 'doing business as'/trading as' MFG Asset Management ('MFG Asset Management') and an investment fund or investment strategy managed by MFG Asset Management ('Strategy'). No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful. This material does not constitute, and may not be used for the purpose of, an offer or solicitation in any jurisdiction or in any circumstances in which such an offer or solicitation is unlawful or not authorized or in which the person making such offer or solicitation is not qualified to do so. This material is not intended to constitute advertising or advice of any kind and you should not construe the contents of this material as legal, tax, investment or other advice.

The investment program of the Strategy presented herein is speculative and may involve a high degree of risk. The Strategy is not intended as a complete investment program and is suitable only for sophisticated investors who can bear the risk of loss. The Strategy may lack diversification, which can increase the risk of loss to investors. The Strategy's performance may be volatile. The past performance of the Strategy is not necessarily indicative of future results and no person guarantees the performance of the Strategy or the amount or timing of any return from it. There can be no assurance that the Strategy will achieve any targeted returns, that asset allocations will be met or that the Strategy will be able to implement its investment Strategy or achieve its investment objective. The management fees, incentive fees and allocation and other expenses of the Strategy will reduce trading profits, if any, or increase losses. The Strategy will have limited liquidity, no secondary market for interests in the Strategy is expected to develop and there are restrictions on an investor's ability to withdraw and transfer interests in the Strategy. In making an investment decision, you must rely on your own examination of any offering documents relating to the Strategy.

No representation or warranty, express or implied, is made with respect to the correctness, accuracy, reasonableness or completeness of any of the information contained in this material. This information is subject to change at any time and no person has any responsibility to update any of the information provided in this material. MFG Asset Management will not be responsible or liable for any losses, whether direct, indirect or consequential, including loss of profits, damages, costs, claims or expenses, relating to or arising from your use or reliance upon any part of the information contained in this material including trading losses, loss of opportunity or incidental or punitive damages.

This material is strictly confidential and is being provided to you solely for your information and must not be copied, reproduced, published, distributed, disclosed or passed to any other person at any time without the prior written consent of MFG Asset Management. Any trademarks, logos, and service marks contained herein may be the registered and unregistered trademarks of their respective owners. Nothing contained herein should be construed as granting by implication, or otherwise, any licence or right to use any trademark displayed without the written permission of the owner.

United Kingdom - This material does not constitute an offer or inducement to engage in an investment activity under the provisions of the Financial Services and Markets Act 2000 (FSMA). This material does not form part of any offer or invitation to purchase, sell or subscribe for, or any solicitation of any such offer to purchase, sell or subscribe for, any shares, units or other type of investment product or service. This material or any part of it, or the fact of its distribution, is for background purposes only. This material has not been approved by a person authorised under the FSMA and its distribution in the United Kingdom and is only being made to persons in circumstances that will not constitute a financial promotion for the purposes of section 21 of the FSMA as a result of an exemption contained in the FSMA 2000 (Financial Promotion) Order 2005 as set out below. This material is exempt from the restrictions in the FSMA as it is to be strictly communicated only to 'investment professionals' as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (FPO).

United States of America - This material is not intended as an offer or solicitation for the purchase or sale of any securities, financial instrument or product or to provide financial services. It is not the intention of MFG Asset Management to create legal relations on the basis of information provided herein. Where performance figures are shown net of fees charged to clients, the performance has been reduced by the amount of the highest fee charged to any client employing that particular strategy during the period under consideration. Actual fees may vary depending on, among other things, the applicable fee schedule and portfolio size. Fees are available upon request and also may be found in Part II of MFG Asset Management's Form ADV.

The MSCI World Index (Net) is a free-float adjusted market capitalization weighted index that is designed to measure the equity performance of 24 developed markets. Index results assume the reinvestment of all distributions of capital gain and net investment income using a tax rate applicable to non-resident institutional investors who do not benefit from double taxation treaties.

GLOBAL INVESTMENT PERFORMANCE STANDARDS (GIPS®) DISCLOSURE

Magellan Asset Management Limited, doing business as MFG Asset Management in jurisdictions outside Australia and New Zealand, (MFG Asset Management) claims compliance with the Global Investment Performance Standards (GIPS®)

For the purpose of complying with GIPS, the Firm is defined as all discretionary portfolios managed by MFG Asset Management.

The Global Plus composite is a concentrated global equity strategy investing in high quality companies (typically 20-40 stocks). High quality companies are those companies that have sustainable competitive advantages which translate into returns on capital materially in excess of their cost of capital for a sustained period of time. The investment objectives of the Global Plus strategy are to earn superior risk adjusted returns through the business cycle whilst minimising the risk of a permanent capital loss. The minimum market capitalisation for a stock to be included is US\$25 billion. The composite was created in July 2013.

To achieve investment objectives, the composite may also use derivative financial instruments including, but not limited to, options, swaps, futures and forwards. Derivatives are subject to the risk of changes in the market price of the underlying securities instruments, and the risk of the loss due to changes in interest rates. The use of certain derivatives may have a leveraging effect, which may increase the volatility of the composite and may reduce its returns.

A copy of the composite's GIPS compliant presentation and/or the firm's list of composite descriptions are available upon request by emailing client.reporting@magellangroup.com.au

The representative portfolio is an account in the composite that closely reflects the portfolio management style of the strategy. Performance is not a consideration in the selection of the representative portfolio. The characteristics of the representative portfolio may differ from those of the composite and of the other accounts in the composite. Information regarding the representative portfolio and the other accounts in the composite is available upon request.

USD is the currency used to calculate performance.

GLOBALPLSUSD43373

Market Commentary

Global stocks rose over the September quarter, to mark their ninth gain in the past 10 quarters, after companies posted higher-than-expected earnings, the US economy expanded briskly, the Federal Reserve reaffirmed that monetary policy would only be tightened gradually and Japan's economy rebounded. Gains were capped when the US escalated its trade war with China, US bond yields rose on inflationary pressures, a higher US dollar buffeted emerging markets and investors fretted about the impasse over the UK's departure from the EU.

US stocks reached unprecedented heights in September as companies reported strong earnings growth and the economy hummed. Financial research and data company FactSet said that 80% of S&P 500 companies announced earnings per share for the second quarter that beat estimates – a 'beat rate' that is the highest since FactSet began tracking this measure in 2008. In September, the Fed raised the US cash rate by a quarter point to between 2% and 2.25% and, as expected, signalled another five rate increases into 2020. The Fed made its eighth post-crisis rate increases on signs that the US economy was growing at close to capacity. Over the three months, reports showed the US economy completed nine years of consecutive growth (June 2009 to June 2018) when it expanded an annualised 4.2% in the June quarter, its fastest pace in four years. The US jobless rate stayed close to the 18-year low of 3.8% set in May and consumer confidence hit an 18-year high in September (as measured by the Conference Board). Gains were capped when the US and China tit-for-tat tariff enactments widened to about half their traded goods and 10-year US government bond yields rose 21 basis points over the three months to 3.06% on inflation concerns.

European stocks rose after European companies posted higher-than-expected earnings, US and European trade tensions eased and Sweden's mainstream parties held off populists in elections. In July, US President Donald Trump and EC President Jean-Claude Juncker met and agreed to "work together toward zero tariffs, zero non-tariff barriers, and zero subsidies on non-auto industrial goods", a statement that boosted hopes the US and EU would avoid a trade war. Sweden's centrist parties did better than expected in the country's election to prevent the populist Sweden Democrats from holding a pivotal, rather than nuisance, position in negotiations to form a government, even though the mainstream parties failed to win enough support to immediately mould a coalition. Gains were capped when the EU rejected the latest withdrawal agreement offered by the UK and Italy's new populist government said it was aiming for a budget deficit of 2.4% in 2019, three times the shortfall of the previous government and in breach of EU budget requirements for indebted governments. Reports showed the eurozone and EU economies expanded 0.4% in the second quarter, the same rate as for the first quarter.

Japanese stocks rose as the economy bounced back to expand 1.9% in the June quarter, after contracting in the previous quarter, and pro-stimulus Prime Minister Shinzō Abe overcame a corruption scandal to win a third term as leader of the Liberal Democratic Party, which allows him to stay in office for three more years. In China, stocks struggled amid concerns about the trade war with the US and as signs emerged the economy is cooling. Emerging markets fell as the collapse in Argentina's and Turkey's currencies presaged financial crises in these countries and Brazil's presidential election in October created uncertainty.

Strategy Commentary

The strategy recorded a positive return for quarter. The stocks that performed best included the investments in HCA Healthcare, Apple and Lowe's. HCA rallied after the US hospital chain reported higher-than-expected profits and revenue for the second quarter and raised guidance for the full year due to higher patient numbers and an increase in higher-paying procedures. Apple surged (to become the first US company with a market value in excess of US\$1 trillion) after the consumer-technology company recorded higher-than-expected earnings for the third quarter and boosted its sales forecast for the fourth quarter due to the high demand for iPhones and other services. Lowe's climbed after the retailer's new CEO told a conference of his plans to simplify the company's operations, lift store productivity, improve service levels and boost longer-term returns.

Stocks that lagged included the investments in Facebook, Kraft Heinz and eBay. Facebook slid after management said slower revenue growth and higher costs would reduce profit margins from about 45% to about 35%, the Instagram founders left and the company revealed that 50 million accounts had been hacked. Kraft Heinz fell after issuing lower earnings guidance for fiscal 2018 even though management indicated renewed focus on improving organic growth. Online auction site owner eBay dropped after the company trimmed its forecast for full-year revenue amid lower-than-expected growth in its Marketplace and StubHub (online ticket exchange) businesses and slower-than-expected progress in the company's 'structured data' initiative, which is an attempt to standardise data related to product display.

Key Stock in Focus – Reckitt Benckiser



Reckitt Benckiser: The consumer-goods multi-national thinks health brands will help in a disruptive world.

Reckitt Benckiser, a UK-based consumer-goods giant now called RB that as recently as 2015 achieved comparable annual sales growth of 6%, could well symbolise how tough conditions are for Big Brands in the age of rising ecommerce and private label penetration.

The company that boasts Clearasil acne treatment, Dettol antiseptic products, Finish washing detergent and Nurofen painkillers among its brands posted zero sales growth in 2017, its worst annual performance since it was formed in a merger in 1999. That result included RB's first-ever declines in comparable quarterly sales; they dropped 2% and 1% in the second and third quarters last year respectively.

The problems for a company that earned 11.5 billion euros in revenue in fiscal 2017 from brands stocked in more than 180 countries, were many over a year during which it divided itself into two businesses – health, which provides 50.5% of sales, and hygiene home, a split the company dubbed 'RB 2.0'. RB, which changed its name from Reckitt Benckiser in 2014, was hit by the 'NotPetya' ransomware cyberattack that hurt production and distribution for up to six months. The Scholl Amope foot care product launch flopped. A boycott in South

Korea over deaths from a noxious humidifier sanitiser lingered. A new goods and services tax in India slowed consumer spending there. RB shares fell 11% over the last six months of 2017 as the company cut forecasts for sales growth.

While like-for-like revenue has risen so far in fiscal 2018 – it gained 2% and 4% in the first and second quarters respectively – and RB shares rose 3.2% over the first nine months of 2018, the company faces a challenge to regain the trust of long-term investors and RB is well primed to do just that. The company in recent years has turned to health because it is a high-growth segment due to favourable demographics and one that provides opportunities for consolidation due to its fragmentation. A benefit of the move to acquire health brands is that it helps insulate RB against the ecommerce and private-label threats harming many 'Big Brand' companies. RB's bet on health brands is that they will maintain their higher margins, are harder to disrupt, promise faster growth, offer greater scope for innovation and are ripe for consolidation.

With the shift to health, the well-managed RB is among the most-disruption proof of Big Brand companies because nearly two-thirds of revenue (net of what suppliers get) comes from brands that are number one or number two in their categories and RB's goods are popular in fast-growing emerging markets, especially China. We invested in RB early in 2018 because we judged the stock to be attractively priced, especially when considering that many of the growth impediments in 2017 were one-offs.

RB, to be sure, has challenges. There is no escaping that all Big Brand household-good companies are losing pricing power as retailers consolidate and shoppers move online, though those brands outside the top two leading positions are most vulnerable. Another risk is that RB, which is always eyeing takeovers, might pay too much to expand. So far so good; management this year pulled out of a bid for Pfizer's consumer health arm due to concerns about overpaying and taking on too much. Emerging economies, which provide nearly half of revenue, are also higher-risk markets on which to depend. RB's management team under Rakesh Kapoor since 2011, which is regarded among the best in the industry on operations and strategy, is managing these risks. Such a team overseeing stellar health Big Brands is likely to keep RB investors happy enough for the foreseeable future.

Well insulated

In 1819, Isaac and Thomas Reckitt built a mill in the UK. In 1823, Johann Benckiser founded an industrial chemicals business in Germany. After nearly 200 years of business and innovation, which included the invention of Mortein fly spray in 1880, Lysol disinfectant in 1899 and Disprin in 1948, the surnames were joined atop one company 19 years ago when Reckitt & Colman merged with the, by then, Netherlands-based Benckiser.

The consumer giant that emerged from this union largely sold 'home products' such as laundry detergent, bar soap and insecticides. In the next two decades, RB expanded into health via takeovers, asset sales, a spin-off and organic growth.

The pivotal takeovers started in 2005, when only 5% of the company's sales were derived from health. In that year, RB bought Boots, and that came with Nurofen and Strepsils. In

2008, the company purchased Adams Respiratory Therapeutics, which owned Mucinex. In 2010, RB acquired SSL International, which came with Durex and Scholl. In 2012, it purchased Schiff Nutrition to branch into vitamins and supplements. The last big swoop was on Mead Johnson in 2017 that signalled the entry into baby formula. Amid these takeovers, RB spun off the pharmaceutical business Indivior in 2014 and sold its food brands to McCormick in 2017.

The strategy RB has for its two business units is clear. Within the best categories, the company aims to offer innovative market-leading products and market these products at prices significantly above the competition. RB calculates that, even though it charges higher prices, it can boost volumes by applying to pharmaceuticals the marketing techniques it honed to sell 'fast-moving consumer goods'.

What sets RB above competitors is how well the company is managed. RB has pursued categories that allow it to achieve the highest margins of all its counterparts. With a culture of controlling costs, streamlining supply networks, developing staff and robust management performance targets (that led to Kapoor having his pay package reduced in 2016 and 2017 due to the company's disappointing results), we expect RB to provide decent returns in coming years.

RB's revenue is diversified from a geographic point of view. About 47% of RB's revenue is derived from fast-growing emerging markets; mainly from China (13%), Brazil (5%) and India (4%, a number that should grow as India builds 110 million toilets as part of a five-year 'Clean India' campaign). About 32% of RB's sales come from the US and 22% from Western Europe.

About 44% of RB's global sales are in categories that we consider to be at moderate or high risk of being replaced by private labels. About 40% of global sales face moderate risk of migrating online. These products include baby food and vitamins.

Given such product positioning and management's nous and strategy, we expect RB to achieve a 3% to 4% p.a. annual revenue growth rates in coming years while modestly improving its profit margin from about 27%. While the growth rates would be half or a third below what RB achieved only three years ago, such results would rank as feats in the disrupted world of Big Brands.

Sources: Company filings and website.